Radiopharma rivals ITM and Telix merge after FDA rejection
Two leading radiopharmaceutical companies are joining forces just as one of them absorbs a surprise regulatory setback.
ITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two prominent players in the radiopharmaceuticals field, are merging. The deal brings together companies that have been competing to develop targeted radioactive therapies for cancer and other diseases.
The merger comes shortly after one of the companies received a surprise rejection from the U.S. Food and Drug Administration. The source does not specify which company was rejected or which product was affected, but the timing suggests the regulatory setback played a role in the decision to combine forces.
Radiopharmaceuticals are a rapidly expanding area of medicine, and the merged company is expected to have a stronger position in the market. The source notes that both firms are considered leading companies in the field, but it does not provide details on the financial terms of the merger or how the combined company will be structured.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.